America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research for the treatment of breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What are the future plans for clinical trials involving AOH1996 and its effectiveness against various cancers?
**Interview with Dr. Linda Malkas: Groundbreaking Advances in Cancer Treatment**
**Editor:** Today, we’re joined by Dr. Linda Malkas, a leading researcher at City of Hope Hospital, where a revolutionary cell-killing drug has been developed to target solid tumors. Thank you for being here, Dr. Malkas.
**Dr. Malkas:** Thank you for having me!
**Editor:** Your team has created AOH1996, which targets cancer cells in a novel way. Can you explain how this drug works?
**Dr. Malkas:** Absolutely. AOH1996 targets a variant of the PCNA protein, which is crucial for DNA replication and tumor growth. Think of it like a blizzard that disrupts the operations of an airline. Just as a storm can shut down an airport’s main hub, AOH1996 effectively halts the flow of cancer cells by disrupting their reproductive cycle.
**Editor:** That’s a fascinating analogy! How effective has AOH1996 been during your clinical research?
**Dr. Malkas:** We’ve tested AOH1996 on over 70 cancer cell lines, and the results have been promising. The molecule selectively destroys cancer cells while sparing normal cells, which is a key advance in chemotherapy. It has shown effectiveness against several types of cancer, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers.
**Editor:** What are the next steps for your research?
**Dr. Malkas:** The next phase involves advancing these findings into clinical trials with human patients. We’re excited to see how AOH1996 performs in a clinical setting and to continue our efforts to provide better treatment options for cancer patients.
**Editor:** You’ve highlighted a unique mutation in cancer cells. How does this discovery contribute to the drug’s effectiveness?
**Dr. Malkas:** The unique mutations in the PCNA protein found in cancer cells allow our drug to specifically target those cells. This selectivity is what enables AOH1996 to minimize damage to healthy cells, which is a significant advancement in the field of oncological therapies.
**Editor:** Thank you, Dr. Malkas, for sharing this exciting breakthrough with us. We look forward to hearing more about the future of AOH1996.
**Dr. Malkas:** Thank you! I appreciate the opportunity to discuss our work.
